|
Volumn 343, Issue 7816, 2011, Pages
|
The pros and cons of generic drugs: Yes, they save money. But are they good for us?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTICONVULSIVE AGENT;
ANTIFUNGAL AGENT;
ANTITHYROID AGENT;
GENERIC DRUG;
LISINOPRIL;
SIMVASTATIN;
PRESCRIPTION DRUG;
BIOEQUIVALENCE;
COMPETITION;
COST CONTROL;
DIABETES MELLITUS;
DRUG COST;
DRUG TOLERANCE;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE COST;
HEALTH INSURANCE;
HEART FAILURE;
HUMAN;
HYPERTENSION;
INFECTION;
MEDICARE;
PATENT;
PRESCRIPTION;
PRIORITY JOURNAL;
SHORT SURVEY;
TREATMENT FAILURE;
ARTICLE;
CLINICAL PRACTICE;
ECONOMICS;
PHARMACOKINETICS;
UNITED KINGDOM;
UNITED STATES;
DRUGS, GENERIC;
GREAT BRITAIN;
HUMANS;
PHYSICIAN'S PRACTICE PATTERNS;
PRESCRIPTION DRUGS;
THERAPEUTIC EQUIVALENCY;
UNITED STATES;
|
EID: 79960665257
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.d4584 Document Type: Short Survey |
Times cited : (6)
|
References (9)
|